HSHanna Soini

Hanna Soini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hanna Soini has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk factors affecting treatment outcomes for pulmonary tuberculosis in Finland 2007–2014: a national cohort study

    by Virve Korhonen, Outi Lyytikäinen, Jukka Ollgren, Hanna Soini, Tuula Vasankari, Petri Ruutu

    Background: Major transition in tuberculosis (TB) epidemiology is taking place in many European countries including Finland. Monitoring treatment outcome of TB cases is important for identifying gaps in the national TB control program, in order to strengthen the system. The aim of the study was to identify potential risk factors for non-successful TB treatment outcomes, with a particular focus on the impact of comorbidities. We also evaluated the treatment outcome monitoring system. Methods: All notified microbiologically confirmed pulmonary TB cases in Finland in 2007–2014 were included, except multi-drug resistant (MDR) cases. Nationwide register data were retrieved from: Infectious Diseases Register, Population Register, Cause of Death Register and Hospital Discharge Register. Non-successful outcomes were divided into three groups: death, unsatisfactory outcomes and non-defined outcomes. Logistic regression analyses were used to identify risk factors for non-successful outcomes. Results: Treatment outcomes were notified for 98.6% of study cases (n = 1396/1416). Treatment success rate was 75%. The main reason for non-successful outcome was death (16%), whereas outcomes failed and lost to follow-up were rare (1% together). In a multivariable model, risk factors for death as outcome were increasing age, male gender and Charlson comorbidity index ≥1, for unsatisfactory outcomes non-MDR drug resistance and TB registered in the first study period, and for non-defined outcomes non-MDR drug resistance. Among 50 cases with unsatisfactory outcomes, we observed false outcome allocations in eight (16%), and > 2% of the cases transferred to another country or disappeared before or during treatment. Conclusions: With a high proportion of older population among tuberculosis cases, death is a common treatment outcome in Finland. Comorbidity is an important factor to be incorporated when interpreting and comparing outcome rates. There was a considerable inconsistency in outcome allocation in the monitoring system, which implies that there is need to review the guidelines and provide further training for outcome assessment.


  • Open Access

    Laboratory-based surveillance of COVID-19 in the Greater Helsinki area, Finland, February-June 2020

    by Hanna Jarva, Maija Lappalainen, Oskari Luomala, Pia Jokela, Ae Jääskeläinen, Anne J Jaaskelainen, Hannimari Kallio-Kokko, Eliisa Kekalainen, Laura Mannonen, Hanna Soini, et al.

    Laboratory registry data (80,791 specimens, 70,517 individuals) was used to characterise age- and sex-specific SARS-CoV-2 RT-PCR sampling frequency and positivity rate, and laboratory capacity building in Greater Helsinki, Finland during February-June 2020. While the number of positive cases was similar in males and females, the positivity rate was significantly higher in males. The highest incidence/100,000 was observed in those aged ≥80 years. The proportion of young adults in positive cases increased in late May 2020.


  • Open Access

    Enhanced surveillance for tuberculosis among foreign-born persons, Finland, 2014–2016

    by Pirre E. Räisänen, Hanna Soini, Pirjo Turtiainen, Tuula Vasankari, Petri Ruutu, J. Pekka Nuorti, Outi Lyytikäinen

    Tuberculosis (TB) in foreign-born residents is increasing in many European countries including Finland. We conducted enhanced TB surveillance to collect supplementary information on TB cases among recent immigrants and their children to provide data for revising TB control policies in Finland to take into account the decrease in native cases and increase in foreign-born cases. TB cases were identified from the National Infectious Diseases Register. Data on foreign-born (if not available, most recent nationality other than Finnish) TB cases notified during 2014–2016 (country of birth, date of arrival to Finland, participation in TB screening, date of first symptoms, and details of possible contact tracing) were requested from physicians responsible for regional communicable disease control through a web-based questionnaire. Questionnaires were returned for 203 (65%) of 314 foreign-born TB cases; 36 (18%) were paediatric cases TB was detected in arrival screening in 42 (21%) and during contact tracing of another TB case in 18 (9%); 143 (70%) cases sought care for symptoms or were identified by chance (e.g. chest x-ray because of an accident). Of cases with data available, 48 (24%) cases were diagnosed within 3 months of arrival to Finland, 55 (27%) cases between 3 months and 2 years from arrival, and 84 (42%) cases after 2 years from arrival. Of all the foreign-born cases, 17% had been in a reception centre in Finland and 15% had been in a refugee camp abroad. In addition to asylum seekers and refugees, TB screening should be considered for immigrants arriving from high TB incidence countries, since the majority of TB cases were detected among persons who immigrated to Finland due to other reasons, presumably work or study. Further evaluation of the target group and timing of TB screening is warranted to update national screening guidance.


  • Open Access

    Recurrent tuberculosis in Finland 1995–2013: a clinical and epidemiological cohort study

    by Virve Korhonen, Hanna Soini, Tuula Vasankari, Jukka Ollgren, Pieter W. Smit, Petri Ruutu

    We investigated the epidemiology and prevalence of potential risk factors of tuberculosis (TB) recurrence in a population-based registry cohort of 8084 TB cases between 1995 and 2013. An episode of recurrent TB was defined as a case re-registered in the National Infectious Disease Register at least 360 days from the date of the initial registration. A regression model was used to estimate risk factors for recurrence in the national cohort. To describe the presence of known risk factors for recurrence, patient records of the recurrent cases were reviewed for TB diagnosis confirmation, potential factors affecting the risk of recurrence, the treatment regimens given and the outcomes of the TB episodes preceding the recurrence. TB registry data included 84 patients, for whom more than 1 TB episode had been registered. After a careful clinical review, 50 recurrent TB cases (0.6%) were identified. The overall incidence of recurrence was 113 cases per 100,000 person-years over a median follow up of 6.1 years. For the first 2 years, the incidence of recurrence was over 200/100000. In multivariate analysis of the national cohort, younger age remained an independent risk factor at all time points, and male gender and pulmonary TB at 18 years of follow-up. Among the 50 recurrent cases, 35 patients (70%) had received adequate treatment for the first episode; in 12 cases (24%) the treating physician and in two cases (4%) the patient had discontinued treatment prematurely. In one case (2%) the treatment outcome could not be assessed. In Finland, the rate of recurrent TB was low despite no systematic directly observed therapy. The first 2 years after a TB episode had the highest risk for recurrence. Among the recurrent cases, the observed premature discontinuation of treatment in the first episode in nearly one fourth of the recurrent cases calls for improved training of the physicians.


    • 1 January 2016
      • Vol. 132  (7) , 654-60

    [Recognize tuberculosis--prevent outbreak].

    by Hanna Soini, Hannele Kotilainen, Harri Marttila, Jane Marttila, Risto Pietikäinen, Eeva Ruotsalainen, Pieter Smit, Kirsi Valve, Tuula Vasankari, Outi Lyytikäinen

    The number of tuberculosis cases in Finland has decreased. Cases among immigrants have, however, increased, and the disease may not be recognized early enough. We describe four group exposures to tuberculosis that occurred in Finland, the index patient coming from a country with a high incidence rate of tuberculosis. Over 900 persons were exposed to tuberculosis. Coordination of the surveys was hampered by the fact that several healthcare operators participated in the study. Three index patients had drug-resistant tuberculosis, one of which was multidrug resistant. Extensive operations of tracking and prevention could have been avoided, if the symptoms would have been recognized earlier.

  • Open Access

    Genotypic characterization and historical perspective of Mycobacterium tuberculosis among older and younger Finns, 2008–2011

    by Pieter W. Smit, Marjo Haanperä, Pirre Rantala, David Couvin, Outi Lyytikäinen, Nalin Rastogi, Petri Ruutu, Hanna Soini


  • Open Access

    Inventory study of non-tuberculous mycobacteria in the European Union

    by Marieke J van der Werf, Csaba Ködmön, Vera Katalinić-Janković, Tiina Kummik, Hanna Soini, Elvira Richter, Dimitrios Papaventsis, Enrico Tortoli, Monique Perrin, Dick van Soolingen, et al.

    Since non-tuberculous mycobacteria (NTM) disease is not notifiable in most European Union (EU) and European Economic Area (EEA) countries, the epidemiological situation of the >150 NTM species is largely unknown. We aimed to collect data on the frequency of NTM detection and NTM species types in EU/EEA countries.


    • 1 January 2014
      • Vol. 130  (16) , 1599-605

    [MDR tuberculosis].

    by Hanna Soini, Tuula Vasankari

    The causative agent of MDR tuberculosis is resistant to at least isoniazid and rifampin, and in the case of XDR tuberculosis, also to fluoroquinolones and aminoglycoside. In 2012, 450000 people had MDR tuberculosis and 170000 people died of it. The majority of the cases were reported in South Africa, India, and Russia. In North West Russia nearly one third of the new tuberculosis cases are MDR. In Finland 2-5 new cases of MDR tuberculosis are notified annually, and this far only one case of XDR tuberculosis has been reported. Treatment of MDR tuberculosis lasts longer and costs more than treatment of drug-susceptible tuberculosis. Moreover, the second line drugs used are less effective and have more side effects than the first line drugs.